Sep. 01, 2020

BioVersys Announces CHF 19 Million Financing to Advance Novel AMR Candidates into Clinical Development

BioVersys announces the successful completion of a CHF 19 million Series B financing round to advance its two lead assets of infectious disease candidates into first in human clinical trials and has also strengthened its board with the appointment of Dr. Eduard Holdener.

Press Release